CO6251325A2 - Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) - Google Patents
Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)Info
- Publication number
- CO6251325A2 CO6251325A2 CO09144825A CO09144825A CO6251325A2 CO 6251325 A2 CO6251325 A2 CO 6251325A2 CO 09144825 A CO09144825 A CO 09144825A CO 09144825 A CO09144825 A CO 09144825A CO 6251325 A2 CO6251325 A2 CO 6251325A2
- Authority
- CO
- Colombia
- Prior art keywords
- seq
- human
- variable region
- sequence
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7 o de la SEQ ID NO: 21. 2.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 8, o una secuencia de la región variable de cadena pesada de la SEQ ID NO: 21, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 22. 3.- El anticuerpo de la reivindicación 2, el cual comprende CDRH1, H2 y H3 de las SEQ ID NOs: 1, 2, y 3, respectivamente, o de las SEQ ID NOs: 15, 16, y 17, respectivamente, o una secuencia de CDRL1, L2 y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NOs: 18, 19, y 20, respectivamente. 4.- El anticuerpo de la reivindicación 2, el cual comprende las CDRH1, H2 y H3 de las SEQ ID Nos: 1, 2, y 3, respectivamente, o de las SEQ ID Nos: 15, 16, y 17, respectivamente, y una secuencia de CDRL1, L2, y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NO: 18, 19, y 20, respectivamente. 5.- El anticuerpo de la reivindicación 2, el cual comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 7, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 8, o que comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 21, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 22. 6.- El anticuerpo de la reivindicación 2, el cual es un anticuerpo quimérico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94520507P | 2007-06-20 | 2007-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6251325A2 true CO6251325A2 (es) | 2011-02-21 |
Family
ID=39846944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09144825A CO6251325A2 (es) | 2007-06-20 | 2009-12-17 | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) |
Country Status (20)
Country | Link |
---|---|
US (1) | US8101182B2 (es) |
EP (1) | EP2170957A1 (es) |
JP (1) | JP2010530233A (es) |
KR (1) | KR20100034015A (es) |
CN (1) | CN102027012A (es) |
AR (1) | AR067045A1 (es) |
AU (1) | AU2008265128A1 (es) |
BR (1) | BRPI0813725A2 (es) |
CA (1) | CA2691157A1 (es) |
CL (1) | CL2008001826A1 (es) |
CO (1) | CO6251325A2 (es) |
CR (1) | CR11152A (es) |
EA (1) | EA201000006A1 (es) |
EC (1) | ECSP099812A (es) |
IL (1) | IL202573A0 (es) |
PE (1) | PE20090768A1 (es) |
TN (1) | TN2009000529A1 (es) |
TW (1) | TW200918557A (es) |
WO (1) | WO2008155365A1 (es) |
ZA (1) | ZA200908711B (es) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE362534T2 (de) | 1998-11-13 | 2007-06-15 | Immunex Corp | Menschliche tslp nukleinsäuren und polypeptide |
DK1417231T3 (da) | 2001-07-23 | 2013-07-22 | Immunex Corp | Modificeret human thymisk stromal lymphopoietin |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
AU2008287426B2 (en) * | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
EP2250199B1 (en) * | 2008-02-07 | 2015-09-02 | Merck Sharp & Dohme Corp. | Engineered anti-tslpr antibodies |
AR082163A1 (es) * | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
KR101221649B1 (ko) * | 2010-11-01 | 2013-01-14 | 광주과학기술원 | 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법 |
SG11201600935SA (en) * | 2013-08-09 | 2016-03-30 | Astellas Pharma Inc | Novel anti-human tslp receptor antibody |
BR112016025852B1 (pt) | 2014-05-07 | 2022-11-01 | Amgen Inc | Dispositivo de injeção para aplicação de fármaco |
MX2016014761A (es) | 2014-05-16 | 2017-05-25 | Amgen Inc | Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2). |
JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
EP3206739B1 (en) | 2014-10-14 | 2021-12-01 | Amgen Inc. | Drug injection device with visual and audio indicators |
CN114569716A (zh) | 2014-10-23 | 2022-06-03 | 美国安进公司 | 降低药物制剂的粘度 |
EP3689394A1 (en) | 2014-12-19 | 2020-08-05 | Amgen Inc. | Drug delivery device with live button or user interface field |
WO2016133947A1 (en) | 2015-02-17 | 2016-08-25 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EP3981450A1 (en) | 2015-02-27 | 2022-04-13 | Amgen, Inc | Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
MA55472A (fr) | 2015-09-09 | 2022-02-09 | Novartis Ag | Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules |
MY186352A (en) | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
TWI836745B (zh) | 2015-12-18 | 2024-03-21 | 美商上游生物公司 | 含有抗人類tslp受體抗體之醫藥組成物 |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
DK3429663T3 (da) | 2016-03-15 | 2020-09-28 | Amgen Inc | Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
US10988284B2 (en) | 2016-05-13 | 2021-04-27 | Amgen Inc. | Vial sleeve assembly |
EP3458988B1 (en) | 2016-05-16 | 2023-10-18 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
US20190358411A1 (en) | 2017-01-17 | 2019-11-28 | Amgen Inc. | Injection devices and related methods of use and assembly |
JP7064501B2 (ja) | 2017-02-17 | 2022-05-10 | アムジエン・インコーポレーテツド | 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法 |
CA3052204A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
KR102619150B1 (ko) | 2017-03-09 | 2023-12-27 | 암겐 인코포레이티드 | 약물 전달 장치용 삽입 메커니즘 |
CA3052676A1 (en) | 2017-03-28 | 2018-10-04 | Amgen Inc. | Plunger rod and syringe assembly system and method |
WO2018201064A1 (en) | 2017-04-28 | 2018-11-01 | Amgen Inc. | N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides |
MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018288604B2 (en) | 2017-06-22 | 2023-12-21 | Amgen Inc. | Device activation impact/shock reduction |
WO2018237225A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
IL270784B2 (en) | 2017-07-14 | 2023-11-01 | Amgen Inc | Needle insertion-extraction system with a double torsion spring system |
WO2019018169A1 (en) | 2017-07-21 | 2019-01-24 | Amgen Inc. | PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
AU2018309027A1 (en) | 2017-08-01 | 2020-01-16 | Amgen Inc. | Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry |
SG11202000785VA (en) | 2017-08-01 | 2020-02-27 | Amgen Inc | Systems and methods for performing a real-time glycan assay of a sample |
US20200164155A1 (en) | 2017-08-09 | 2020-05-28 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
IL272636B2 (en) | 2017-10-06 | 2024-10-01 | Amgen Inc | Drug delivery device with combination assembly and related assembly method |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
MA50527A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Système et approches pour stériliser un dispositif d'administration de médicament |
EP3706830B1 (en) | 2017-11-06 | 2024-08-07 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
US11191904B2 (en) | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
JP7370969B2 (ja) | 2017-11-16 | 2023-10-30 | アムジエン・インコーポレーテツド | 薬物送達デバイスの扉ラッチ機構 |
WO2019178151A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
MA52015A (fr) | 2018-03-13 | 2021-01-20 | Amgen Inc | Digestion séquentielle de polypeptides pour une analyse par spectrométrie de masse |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
KR102682705B1 (ko) * | 2018-07-04 | 2024-07-05 | 고려대학교 세종산학협력단 | 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물 |
EP3826701A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
US12115360B2 (en) | 2018-07-24 | 2024-10-15 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023451A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
CA3103105A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
WO2020068623A1 (en) | 2018-09-24 | 2020-04-02 | Amgen Inc. | Interventional dosing systems and methods |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CN112805048B (zh) | 2018-10-02 | 2023-09-22 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
MA53818A (fr) | 2018-10-05 | 2022-01-12 | Amgen Inc | Dispositif d'administration de médicament ayant un indicateur de dose |
IL281894B1 (en) | 2018-10-15 | 2024-08-01 | Amgen Inc | A drug delivery device with a suppression mechanism |
SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
EP3894839A1 (en) | 2018-12-14 | 2021-10-20 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
AU2020221372A1 (en) | 2019-02-14 | 2021-08-19 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
US20220137010A1 (en) | 2019-02-20 | 2022-05-05 | Amgen Inc. | Methods of determining protein stability |
MX2021010414A (es) | 2019-03-04 | 2021-09-14 | Amgen Inc | Reversibilidad in vivo de especies de alto peso molecular. |
WO2020198538A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
JP7510952B2 (ja) | 2019-04-24 | 2024-07-04 | アムジエン・インコーポレーテツド | シリンジ滅菌確認アセンブリ及び方法 |
KR20220016897A (ko) | 2019-06-04 | 2022-02-10 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 흉선 기질 림포포이에틴에 결합할 수 있는 항체 및 이의 용도 |
AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
CN111171150B (zh) * | 2020-02-05 | 2020-12-08 | 北京智仁美博生物科技有限公司 | 抗人tslp抗体及其用途 |
JP2023543167A (ja) | 2020-09-18 | 2023-10-13 | アムジエン・インコーポレーテツド | ペプチドマッピング分析のための試料を処理する方法 |
US20240010672A1 (en) | 2020-11-05 | 2024-01-11 | Amgen Inc. | Materials and methods for protein processing |
KR20240011135A (ko) | 2021-05-21 | 2024-01-25 | 암젠 인크 | 약물 용기를 위한 충전 레시피를 최적화하는 방법 |
EP4430174A1 (en) | 2021-11-09 | 2024-09-18 | Amgen Inc. | Production of therapeutic proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE490980T1 (de) | 1998-03-19 | 2010-12-15 | Human Genome Sciences | Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor |
WO2002000723A2 (en) | 2000-06-28 | 2002-01-03 | Whitehead Institute For Biomedical Research | Thymic stromal lymphopoietin receptor molecules and uses thereof |
WO2002000724A2 (en) * | 2000-06-28 | 2002-01-03 | Amgen, Inc. | Thymic stromal lymphopoietin receptor molecules and uses thereof |
US6890734B2 (en) | 2000-11-10 | 2005-05-10 | Schering Corporation | Nucleic acids encoding a cytokine receptor complex |
WO2003065985A2 (en) * | 2002-02-01 | 2003-08-14 | Schering Corporation | Uses of mammalian cytokine; related reagents |
PL1651247T3 (pl) * | 2003-07-18 | 2009-04-30 | Schering Corp | Leczeni i diagnozowanie nowotworów przy użyciu limfopoetyny zrębu grasicy |
US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
WO2006023791A2 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
US20060171943A1 (en) | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
JP5258578B2 (ja) * | 2006-01-13 | 2013-08-07 | アイアールエム・リミテッド・ライアビリティ・カンパニー | アレルギー性疾患を処置するための胸腺間質性リンホポエチン受容体に対する抗体 |
EP2250199B1 (en) | 2008-02-07 | 2015-09-02 | Merck Sharp & Dohme Corp. | Engineered anti-tslpr antibodies |
-
2008
- 2008-06-18 PE PE2008001045A patent/PE20090768A1/es not_active Application Discontinuation
- 2008-06-18 CA CA2691157A patent/CA2691157A1/en not_active Abandoned
- 2008-06-18 JP JP2010512681A patent/JP2010530233A/ja active Pending
- 2008-06-18 EA EA201000006A patent/EA201000006A1/ru unknown
- 2008-06-18 AR ARP080102594A patent/AR067045A1/es not_active Application Discontinuation
- 2008-06-18 EP EP08761179A patent/EP2170957A1/en not_active Withdrawn
- 2008-06-18 WO PCT/EP2008/057731 patent/WO2008155365A1/en active Application Filing
- 2008-06-18 US US12/141,516 patent/US8101182B2/en not_active Expired - Fee Related
- 2008-06-18 AU AU2008265128A patent/AU2008265128A1/en not_active Abandoned
- 2008-06-18 BR BRPI0813725-0A2A patent/BRPI0813725A2/pt not_active IP Right Cessation
- 2008-06-18 CN CN2008801025460A patent/CN102027012A/zh active Pending
- 2008-06-18 KR KR1020107001185A patent/KR20100034015A/ko not_active Application Discontinuation
- 2008-06-19 TW TW097122910A patent/TW200918557A/zh unknown
- 2008-06-19 CL CL2008001826A patent/CL2008001826A1/es unknown
-
2009
- 2009-12-07 IL IL202573A patent/IL202573A0/en unknown
- 2009-12-08 ZA ZA200908711A patent/ZA200908711B/xx unknown
- 2009-12-09 CR CR11152A patent/CR11152A/es not_active Application Discontinuation
- 2009-12-17 TN TNP2009000529A patent/TN2009000529A1/fr unknown
- 2009-12-17 CO CO09144825A patent/CO6251325A2/es not_active Application Discontinuation
- 2009-12-18 EC EC2009009812A patent/ECSP099812A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TN2009000529A1 (en) | 2011-03-31 |
EP2170957A1 (en) | 2010-04-07 |
ZA200908711B (en) | 2010-08-25 |
WO2008155365A1 (en) | 2008-12-24 |
PE20090768A1 (es) | 2009-07-09 |
US8101182B2 (en) | 2012-01-24 |
JP2010530233A (ja) | 2010-09-09 |
KR20100034015A (ko) | 2010-03-31 |
CA2691157A1 (en) | 2008-12-24 |
TW200918557A (en) | 2009-05-01 |
BRPI0813725A2 (pt) | 2014-12-30 |
CN102027012A (zh) | 2011-04-20 |
AR067045A1 (es) | 2009-09-30 |
CL2008001826A1 (es) | 2009-02-20 |
EA201000006A1 (ru) | 2010-10-29 |
CR11152A (es) | 2010-01-20 |
AU2008265128A1 (en) | 2008-12-24 |
IL202573A0 (en) | 2011-08-01 |
US20090074747A1 (en) | 2009-03-19 |
ECSP099812A (es) | 2010-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6251325A2 (es) | Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
CR11030A (es) | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
AR083747A1 (es) | Anticuerpos anti-il-23 | |
AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
CR20130351A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819) | |
AR063090A1 (es) | Proteinas de union al antigeno del receptor de la il-17 | |
PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
NZ717847A (en) | Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof | |
ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
PE20120429A1 (es) | Proteinas de enlace de miostatina | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
PE20121361A1 (es) | Antagonistas de pcsk9 | |
PE20120414A1 (es) | Proteinas biespecificas tetravalentes de union a antigeno | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
PE20120306A1 (es) | Anticuerpos anti-egfr y vectores que los codifican | |
PE20150222A1 (es) | Anticuerpos multiespecificos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |